TICKERNERD
Menu
RNACRNACHealthcare · Biotechnology

RNAC Stock Forecast: Cartesian Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$10
−1.91% on the day

The 8 Wall Street analysts covering Cartesian Therapeutics, Inc. hold a median 12-month price target of $39 — +288.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$303.8M
Ticker Nerd rank
25 / 100
Median analyst target
$39
Analysts covering
8
Total return, dividends reinvested
1W
+13.5%
1M
+23.4%
YTD
+39.2%
1Y
−8.4%
From 52W high
−10.8%
From 52W low
+71.8%
$6
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RNAC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cartesian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
89
Size
63
Revisions
48
Momentum
44
Value
39
Quality
32
Volatility
32
Growth
8
Issuance
6

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RNAC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNAC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26RNACHigh $44Median $39Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $16Median $39High $44

The green dot is the last close — the median target sits +288.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026WedbushReiteratesOutperform$38
10 June 2026WedbushReiteratesOutperform$38
10 June 2026WedbushReiteratesOutperform—
9 June 2026BTIGReiteratesBuy$44
9 June 2026BTIGReiteratesBuy—
9 June 2026NeedhamReiteratesBuy$40
9 June 2026NeedhamReiteratesBuy—
27 May 2026WedbushReiteratesOutperform—
26 May 2026NeedhamMaintainsBuy—
12 May 2026HC Wainwright & Co.MaintainsBuy—
1 May 2026WedbushReiteratesOutperform—
10 Mar 2026WedbushReiteratesOutperform—
9 Mar 2026Cantor FitzgeraldUpgradeOverweight—
9 Mar 2026NeedhamReiteratesBuy—
9 Jan 2026NeedhamMaintainsBuy—
19 Nov 2025HC Wainwright & Co.MaintainsBuy—
14 Nov 2025BTIGMaintainsBuy—
9 July 2025WedbushInitiatesOutperform—
8 May 2025NeedhamMaintainsBuy—
9 Apr 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNAC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RNAC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Cartesian Therapeutics, Inc. (RNAC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.0×

Cheaper than 70% of US stocks

Price / sales
205.7×

Cheaper than 3% of US stocks

Price / book
−2.4×

Cheaper than 96% of US stocks

EV / EBITDA
−2.3×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−0.7%

Higher than 35% of US stocks

Gross margin
—
Operating margin
−6679.7%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
103.2%

Higher than 96% of US stocks

Return on assets
−17.4%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RNAC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNACCartesian Therapeutics, Inc.$303.8M
25
TRDAEntrada Therapeutics, Inc.$293.9M
51
IVVDInvivyd, Inc.$293.6M
19
FULCFulcrum Therapeutics, Inc.$292.2M
36
NMRANeumora Therapeutics, Inc.$296.7M
36
AVXLAnavex Life Sciences Corp.$300.3M
21
VRXAVERAXA Biotech AG$288.1M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cartesian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RNAC news & analysis

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewsWire · 7 Aug 2026neutral

Cartesian Therapeutics announced it granted inducement stock option awards to four new employees, covering an aggregate of 115,250 shares of its common stock, with effective grant dates of August 3, 2026 and August 6, 2026.

Why it matters — A Cartesian Therapeutics watcher would note that the company is adding new hires through equity-based inducement awards as it advances cell therapy for autoimmune diseases.

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 6 Aug 2026neutral

Cartesian Therapeutics reported its second quarter 2026 financial results and issued a business update. The Phase 3 AURORA trial of Descartes-08 in myasthenia gravis is continuing, with data expected in the first quarter of 2027 and a biologics license application filing planned for mid-2027.

Why it matters — For RNAC watchers, the anticipated AURORA trial data and planned BLA filing mark key upcoming milestones for the company's lead product candidate, Descartes-08.

FAQ

Frequently asked questions about RNAC stock

What is the RNAC stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Cartesian Therapeutics, Inc. have a median 12-month price target of $39, with estimates ranging from $16 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RNAC stock a buy right now?

Of the 8 analysts covering Cartesian Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cartesian Therapeutics, Inc. 25 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNAC?

As at 22 Aug 2026, Cartesian Therapeutics, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will RNAC stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +288.6% from the last close, and Ticker Nerd's factor model ranks Cartesian Therapeutics, Inc. 25 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RNAC stock forecast for 2030?

No analyst covering Cartesian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNAC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $44 over the next 12 months.

How has RNAC stock performed over the past year?

Cartesian Therapeutics, Inc. returned -8.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cartesian Therapeutics, Inc. do?

Cartesian Therapeutics Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases.

What is the latest news on RNAC?

The most recent item we track (GlobeNewsWire, 7 Aug 2026): "Cartesian Therapeutics Announces New Employment Inducement Grants". Cartesian Therapeutics announced it granted inducement stock option awards to four new employees, covering an aggregate of 115,250 shares of its common stock, with effective grant dates of August 3, 2026 and August 6, 2026.

Company

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. It utilizes its proprietary ImmTOR immune tolerance platform to induce antigen-specific immunity and mitigate unwanted immune responses, leveraging mRNA technology to enhance cell functions through its manufacturing platform. The lead product candidate, Descartes-08, is an autologous mRNA CAR-T therapy targeting B cell maturation antigen (BCMA) and is in Phase 2b clinical trials for conditions including generalized myasthenia gravis, systemic lupus erythematosus, and juvenile dermatomyositis, which has received rare pediatric disease designation. Additional candidates include Descartes-15, an autologous anti-BCMA mRNA CAR-T for autoimmune diseases and relapsed or refractory multiple myeloma, and Descartes-33 in preclinical development for autoimmune indications. Operating in the healthcare biotechnology sector, Cartesian Therapeutics Inc. advances innovative cell therapy solutions to address unmet needs in autoimmune disorders. Headquartered in Gaithersburg, Maryland, the company concentrates on research and development of these specialized product candidates.

CEO Dr. Carsten Brunn Ph.D. · 75 employees · United States · https://www.cartesiantherapeutics.com